Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
US Department of Justice
Queensland Health
Mallinckrodt
Julphar
Healthtrust
Fish and Richardson
Moodys
Cantor Fitzgerald
Accenture

Generated: October 17, 2017

DrugPatentWatch Database Preview

Sofosbuvir; velpatasvir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for sofosbuvir; velpatasvir and what is the scope of sofosbuvir; velpatasvir patent protection?

Sofosbuvir; velpatasvir
is the generic ingredient in two branded drugs marketed by Gilead Sciences Inc and is included in two NDAs. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sofosbuvir; velpatasvir has three hundred and fifty-seven patent family members in forty-five countries and fourteen supplementary protection certificates in twelve countries.

There are six drug master file entries for sofosbuvir; velpatasvir. One supplier is listed for this compound.

Summary for Generic Name: sofosbuvir; velpatasvir

US Patents:15
Tradenames:2
Applicants:1
NDAs:2
Drug Master File Entries: see list6
Suppliers / Packagers: see list1
Clinical Trials: see list222
Drug Prices:see low prices
DailyMed Link:sofosbuvir; velpatasvir at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VOSEVI
sofosbuvir; velpatasvir; voxilaprevir
TABLET;ORAL209195-001Jul 18, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VOSEVI
sofosbuvir; velpatasvir; voxilaprevir
TABLET;ORAL209195-001Jul 18, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VOSEVI
sofosbuvir; velpatasvir; voxilaprevir
TABLET;ORAL209195-001Jul 18, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: sofosbuvir; velpatasvir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,221,833Antiviral compounds► Subscribe
9,206,217Nucleoside phosphoramidates► Subscribe
8,735,569Nucleoside phosphoramidates► Subscribe
8,629,263Nucleoside phosphoramidates► Subscribe
9,393,256Methods for treating HCV► Subscribe
9,585,906Nucleoside phosphoramidate prodrugs► Subscribe
8,642,756Nucleoside phosphoramidates► Subscribe
9,637,512Nucleoside phosphoramidates► Subscribe
9,051,340Antiviral compounds► Subscribe
8,859,756Stereoselective synthesis of phosphorus containing actives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: sofosbuvir; velpatasvir

Country Document Number Estimated Expiration
CroatiaP20150725► Subscribe
Ukraine110354► Subscribe
China104017020► Subscribe
Canada2794669► Subscribe
Uruguay33735► Subscribe
HungaryE026235► Subscribe
Lithuania2609923► Subscribe
Russian Federation2478104► Subscribe
Japan2016106149► Subscribe
Cyprus1115488► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SOFOSBUVIR; VELPATASVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014040,C2203462Lithuania► SubscribePRODUCT NAME: SOFOSBUVIRAS; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116
2014040Lithuania► SubscribePRODUCT NAME: SOFOSBUVIRUM; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116
00704Netherlands► SubscribePRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
C0082France► SubscribePRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
0140035 00135Estonia► SubscribePRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014
600Luxembourg► SubscribePRODUCT NAME: SOVALDI (SOFOSBUVIR). FIRST REGISTRATION: 20140117
2014000108Germany► SubscribePRODUCT NAME: SOVALDI (SOFOSBUVIR); NAT. REGISTRATION NO/DATE: EU /1/13/894 20140116; FIRST REGISTRATION: EU EU/1/13/894 20140116
4 5029-2014Slovakia► SubscribePRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
/2014Austria► SubscribePRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
2203462/01Switzerland► SubscribePRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: SWISSMEDIC 63218 18.03.2014
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Chubb
Healthtrust
US Department of Justice
Julphar
Merck
Boehringer Ingelheim
McKinsey
Medtronic
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot